Trialtrove-classified anticancer vaccine trials in non-small cell lung cancer: endpoints, attrition, and biomarker use

Background Therapeutic cancer vaccines in non-small cell lung cancer (NSCLC) have been tested for three decades without regulatory approval. Three confirmatory-scale randomized trials reported negative results (vaccine biology), whereas later strategies were never tested at comparable scale (development practice). We characterize the latter. Methods We analyzed 207 interventional NSCLC trials classified by Trialtrove (April 2026) as evaluating anticancer vaccines, manually adjudicating free-text eligibility fields for immune-based criteria. The analyses were descriptive. Results Most trials were early phase (192/207, 92.8%); 78/207 (37.7%) specified no efficacy-oriented primary endpoint (68.2% of phase I, 10.3% of phase II and later). Of 46 terminated trials after enrolment, discontinuation for lack of efficacy ranged from 13.0% to 80.4%, which is too broad for definitive attribution. Immune-based selection was present in 52 trials but was largely limited to HLA restriction (42 trials) and PD-L1 thresholds (11 trials); no trial selected patients on baseline immune contexture. Conclusion Within Trialtrove-labelled vaccine trials in NSCLC, clinical-development architecture has been insufficient to distinguish biological failure from strategies that were never evaluated at a scale able to return a verdict. Combination and biomarker-enriched designs are increasingly common but have not yet demonstrated superior outcomes, accounting for four of the six terminations attributed to lack of efficacy in the cohort, all four of them in immuno-oncology combination trials; whether this reflects biological limitations, inadequate scale, or both cannot be determined from the available data. These findings may not represent the entire NSCLC vaccine field.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.1968573
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trialtrove-classified anticancer vaccine trials in non-small cell lung cancer: endpoints, attrition, and biomarker use

Peiyun Lv, Bao Wang, Kunpeng Yang, Zhongkun Li et al.
1 links
Frontiers in Immunology
Immunotherapy and Immune Responses
article

Trialtrove-classified anticancer vaccine trials in non-small cell lung cancer: endpoints, attrition, and biomarker use

Peiyun Lv, Bao Wang, Kunpeng Yang, Zhongkun Li, Bingqiang Li, Wenjuan Sun, Hang Li, Zhe Wang
article en

Abstract

Background Therapeutic cancer vaccines in non-small cell lung cancer (NSCLC) have been tested for three decades without regulatory approval. Three confirmatory-scale randomized trials reported negative results (vaccine biology), whereas later strategies were never tested at comparable scale (development practice). We characterize the latter. Methods We analyzed 207 interventional NSCLC trials classified by Trialtrove (April 2026) as evaluating anticancer vaccines, manually adjudicating free-text eligibility fields for immune-based criteria. The analyses were descriptive. Results Most trials were early phase (192/207, 92.8%); 78/207 (37.7%) specified no efficacy-oriented primary endpoint (68.2% of phase I, 10.3% of phase II and later). Of 46 terminated trials after enrolment, discontinuation for lack of efficacy ranged from 13.0% to 80.4%, which is too broad for definitive attribution. Immune-based selection was present in 52 trials but was largely limited to HLA restriction (42 trials) and PD-L1 thresholds (11 trials); no trial selected patients on baseline immune contexture. Conclusion Within Trialtrove-labelled vaccine trials in NSCLC, clinical-development architecture has been insufficient to distinguish biological failure from strategies that were never evaluated at a scale able to return a verdict. Combination and biomarker-enriched designs are increasingly common but have not yet demonstrated superior outcomes, accounting for four of the six terminations attributed to lack of efficacy in the cohort, all four of them in immuno-oncology combination trials; whether this reflects biological limitations, inadequate scale, or both cannot be determined from the available data. These findings may not represent the entire NSCLC vaccine field.

Frontiers in ImmunologyVol. 17
Jilin Province Tumor Hospital (CN), Changchun University of Chinese Medicine (CN)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon